RenovoRx Inc - Asset Resilience Ratio

Latest as of December 2023: 0.00%

RenovoRx Inc (RNXT) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check RNXT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$1.47 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2023)

This chart shows how RenovoRx Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of RenovoRx Inc to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down RenovoRx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RNXT market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: RenovoRx Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

RenovoRx Inc Industry Peers by Asset Resilience Ratio

Compare RenovoRx Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for RenovoRx Inc (2021–2023)

The table below shows the annual Asset Resilience Ratio data for RenovoRx Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.00% $0.00 $1.47 Million --
2022-12-31 28.20% $2.05 Million $7.26 Million --
2021-12-31 0.00% $0.00 $16.29 Million --
pp = percentage points

About RenovoRx Inc

NASDAQ:RNXT USA Biotechnology
Market Cap
$40.13 Million
Market Cap Rank
#22934 Global
#4954 in USA
Share Price
$0.89
Change (1 day)
+1.26%
52-Week Range
$0.73 - $1.42
All Time High
$16.02
About

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more